TARGET-PBC: A 5-year Longitudinal Observational Study of Patients with Primary Biliary Cholangitis
Brief description of study
You are being asked to be in this research study because you have PBC (primary biliary cholangitis) which is an uncommon chronic cholestatic liver disease characterized by progressive inflammation and destruction of the interlobular bile ducts, ultimately leading to the development of biliary cirrhosis.
Detailed description of study
The goals of this study are to collect information on patients with PBC to determine the natural course of the liver disease and to determine if certain lifestyle changes or changes in diet or other treatments that may be recommended by your doctors can affect “PBC.”. Currently, there are 2 specific drugs, Ocaliva™ and ursodeoxycholic acid (UDCA), approved by the FDA (the Food and Drug Administration to treat PBC.
This research study aims to observe any treatment for PBC in a large number of people in a “real life” setting. Researchers are interested in observing how these treatments, lifestyle changes, and counseling work in patients who are treated by their doctors in routine practice.
Additional InformationThis is an observational study. This means that none of the procedures that are regularly done in order to treat and monitor your PBC are changed by this observational study. Participating in this study does not change anything that your physician will do or has already done. Decisions about the types of therapies, length (duration), and dosing are determined by you and your physician and not affected by your participation in this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
PBC,liver disease,primary billary Cholangitis
-
Age: Between 18 Years - 80 Years
-
Gender: All
Updated on
24 Jul 2023.
Study ID: 826565
